scholarly journals Association between inflammatory bowel diseases and Parkinson’s disease: systematic review and meta-analysis

2022 ◽  
Vol 17 (2) ◽  
pp. 344
Author(s):  
Zheng-Bing Xiang ◽  
Ren-Shi Xu ◽  
Yu Zhu ◽  
Min Yuan ◽  
Yue Liu ◽  
...  
2015 ◽  
Vol 149 (4) ◽  
pp. 928-937 ◽  
Author(s):  
Sunny Singh ◽  
Ahmed Al-Darmaki ◽  
Alexandra D. Frolkis ◽  
Cynthia H. Seow ◽  
Yvette Leung ◽  
...  

Angiology ◽  
2016 ◽  
Vol 68 (5) ◽  
pp. 447-461 ◽  
Author(s):  
Guo-Cui Wu ◽  
Rui-Xue Leng ◽  
Qi Lu ◽  
Yin-Guang Fan ◽  
De-Guang Wang ◽  
...  

We evaluated the differences in major markers of cardiovascular (CV) risk between inflammatory bowel diseases (IBDs) and controls by a systematic review and a meta-analysis. We searched PubMed, EMBASE, and Cochrane databases for literature comparing CV risk markers in IBDs and controls. The overall mean carotid intima–media thickness (CIMT), flow-mediated dilation (FMD%), and carotid–femoral pulse wave velocity (cfPWV) difference between patients with IBDs and control groups were calculated. Twenty-eight studies were included in the meta-analysis, including 16 studies with data on CIMT, 7 studies reporting FMD%, and 9 studies on cfPWV. Compared to controls, patients with IBDs showed significantly higher CIMT (standardized mean difference [ SMD]: 0.534 mm; 95% confidence interval [CI], 0.230 to 0.838; P = .001), significantly lower FMD% ( SMD, −0.721%; 95% CI, −1.020 to −0.421; P < .0001), and significantly increased cfPWV ( SMD, 0.849; 95% CI, 0.589 to 1.110; P < .0001). When analyzing subgroups with ulcerative colitis and Crohn disease (CD), all results were still significant except CIMT in CD. Our findings support the current evidence for an elevated CV burden in patients with IBD and support the clinical utility of markers of subclinical atherosclerosis in the management of these patients.


Sign in / Sign up

Export Citation Format

Share Document